July 11, 2022
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

SymBio announces the publication of the results of its Phase I/II clinical study of the rapid infusion (RI) administration of TREAKISYM® liquid formulation

TOKYO, Japan, July 11, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio" or the "Company") today announced that the results of its Phase I/II clinical study in Japan to investigate the safety, tolerability, pharmacokinetics, and efficacy of the 10-minute administration of TREAKISYM® ready-to-dilute (RTD) liquid formulation in combination with rituximab ("BR therapy") in patients with previously untreated indolent B-cell non-Hodgkin lymphoma (iNHL) or mantle cell lymphoma (MCL), and patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), were published in the Cancer Chemotherapy and Pharmacology (CCP) medical journal. Based on the results of this clinical trial, TREAKISYM® RI administration was approved in February 2022.

For more information, the article can be viewed online at:
https://link.springer.com/article/10.1007/s00280-022-04442-2

TREAKISYM® RI administration has a lower infusion volume (approximately 50 ml vs. 250 ml) and a faster infusion time (10 minutes vs. 60 minutes). In addition to the significant benefits to patients and healthcare professionals resulting from TREAKISYM® RI administration's reduced infusion time, the lower infusion volume means the infusion has lower salt content, which benefits patients with dietary sodium restrictions.

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125

About TREAKISYM®

TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug first used in Germany in the 1970s, is now widely used in more than 50 countries with indications for low-grade non-Hodgkin's lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.

- TREAKISYM® Intravenous Infusion 100 mg was approved in October 2010 for manufacturing and marketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan.
- TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia in Japan in August 2016.
- TREAKISYM® was approved for the additional indications of first-line treatment of low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan in December 2016.
- SymBio obtained approval for the marketing of TREAKISYM® Intravenous Drip Infusion 100mg/4mL (RTD, ready-to-dilute, liquid formulation) for all the above indications in September 2020.
- TREAKISYM® FD and RTD formulations were approved for the additional indication of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) in March 2021 and April 2021, respectively.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, the Company incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Durham, North Carolina, President: Dr. Carolyn Yanavich).
The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.